Form 4: UTHR CFO Edgemond Reports Stock Transactions

United Therapeutics CFO James Edgemond reported the vesting of restricted stock units and subsequent tax-related share withholdings, alongside an Employee Stock Purchase Plan acquisition.

Summary

• James Edgemond, CFO and Treasurer of United Therapeutics Corporation (UTHR), reported several transactions involving company stock.
• On March 15, 2026, 10,380 performance-based restricted stock units (RSUs) vested and converted into common stock. These RSUs were granted on March 15, 2023.
• Also on March 15, 2026, an additional 9,098 performance-based RSUs vested and converted into common stock, also granted on March 15, 2023.
• United Therapeutics withheld a total of 8,786 shares (4,682 and 4,104 shares) for tax purposes upon the vesting of these RSUs, at a price of $536.12 per share.
• An acquisition of 42 shares of common stock occurred on March 4, 2026, under the United Therapeutics Employee Stock Purchase Plan.
• Following these transactions, Edgemond's direct beneficial ownership of common stock was 18,876 shares after the second tax withholding.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine disclosure of executive compensation realization, with the vesting of performance-based RSUs indicating past performance achievement and the ESPP acquisition showing minor insider confidence.

Positives

• The vesting of 19,478 performance-based restricted stock units (10,380 + 9,098) for CFO James Edgemond indicates the achievement of specific performance metrics over the three-year vesting period from their grant date of March 15, 2023.
• The acquisition of 42 shares through the Employee Stock Purchase Plan on March 4, 2026, demonstrates continued insider participation and confidence in the company's stock.

Negatives

• A total of 8,786 shares of common stock were withheld by United Therapeutics for tax obligations related to the RSU vesting, representing a disposition of shares from the CFO's direct beneficial ownership.

Industry Context

StockSavvy.ai notes that insider transactions, particularly the vesting of performance-based equity awards, are a standard component of executive compensation in the biotechnology and pharmaceutical industries. The Employee Stock Purchase Plan acquisition, while small, is a minor positive signal of continued insider investment.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to executive compensation and an employee stock purchase plan. While the vesting of performance-based restricted stock units indicates past achievement, and the ESPP acquisition shows minor insider confidence, these transactions are not significant enough to alter the fundamental investment thesis for United Therapeutics Corporation. Investors should consider broader company performance and market conditions for a comprehensive view.

Keywords

UTHR, United Therapeutics, Form 4, Insider Trading, Stock Transactions, Restricted Stock Units, Employee Stock Purchase Plan, CFO, James Edgemond